FDA Panel Votes 9-3 Against Capricor’s Duchenne Heart Therapy Over Weak Evidence
Final decision due Aug. 22.
/ 492 items
#XY Event-Driven Stocks↓
FTC Sues Hims & Hers for Sharing Health Data with Meta and Snap
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis
FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.
FDA Grants Priority Review to PolyPid’s D-PLEX100 for Surgical Infection Prevention
PDUFA date set for Nov 28, 2026, triggering $15M milestone.
Processa Adds Next-Gen BTK Inhibitor VT-7208, Secures $200M Funding Into 2029 — But Ownership Shifts Dramatically
Processa acquires VT-7208, a next-gen brain-penetrant BTK inhibitor for food allergy, CSU & MS. $200M raise funds trials into 2029.
Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.